Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-P01 + PD-1 + RFA in Advanced Solid Tumors
NCT04864379Phase 1Unknown
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Sep 2020
- Primary completion
- Aug 2025
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iNeo-Vac-P01 in solid tumor (advanced stage) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Adverse Events at 1 year, Objective Response Rate at 5 years and 2 more. Status: unknown.
02
Drugs
iNeo-Vac-P01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04864379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864379.